Which spinal lesions are associated with new bone formation in patients with ankylosing spondylitis treated with anti-TNF agents? A long-term observational study using MRI and conventional radiography

Annals of the Rheumatic Diseases

Volumn 73, Issue 10, 2014, Pages 1819-1825

  Baraliakos, X ^a   Heldmann, F ^a   Callhoff, J ^b   Listing, J ^b   Appelboom, T ^c   Brandt, J ^d   Van Den Bosch, F ^e   Breban, M ^f   Burmester, G R ^d   Dougados, M ^g   Emery, P ^h,i   Gaston, H ^j   Grunke, M ^k   Van Der Horst Bruinsma, I E ^l   Landewe R ^m   Leirisalo Repo, M ⁿ   Sieper, J ^d   De Vlam, K ^o   Pappas, D ^p   Kiltz, U ^a   Van Der Heijde, D ^q   Braun, J ^a   more..

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b German Rheumatism Research Center   (Germany)

^c ERASME HOSPITAL   (Belgium)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e GHENT UNIVERSITY HOSPITAL   (Belgium)

^f LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h UNIVERSITY OF LEEDS   (United Kingdom)

ⁱ LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF MUNICH   (Germany)

^l VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^m MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁿ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^o UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^p ST ANNA HOSPITAL   (Germany)

^q LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ADULT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; MALE; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSSIFICATION, HETEROTOPIC; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING;

ADIPOSE TISSUE; ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; OSSIFICATION, HETEROTOPIC; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84881071746     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203425     Document Type: Article

References (38)

1. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44.
2. Braun J, Baraliakos X, Golder W, et al. Analysing chronic spinal changes in ankylosing spondylitis: a systematic comparison of conventional x rays with magnetic resonance imaging using established and new scoring systems. Ann Rheum Dis 2004;63:1046-55.
3. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-15.
4. Van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011;70:905-8.
5. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008;10:R104.
6. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
7. Van der Heijde D, Machado P, Braun J, et al. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:369-73.
8. Braun J, Landewe R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
9. Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 2005;64:1462-6.
10. Van der Heijde D, Landewe R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
11. Van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
12. Van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
13. Baraliakos X, Listing J, Brandt J, et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 2007;46:1450-3.
14. Poddubnyy D, Rudwaleit M, Haibel H, et al. Effect of non-steroidal antiinflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 2012;71:1616-22.
15. Kroon F, Landewé R, Dougados M, et al. Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 2012;71:1623-9.
16. Baraliakos X, Haibel H, Listing J, et al. Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 2014;73:710-5.
17. Baraliakos X, Listing J, Von der Recke A, et al. The natural course of radiographic progression in ankylosing spondylitis-evidence for major individual variations in a large proportion of patients. J Rheumatol 2009;36:997-1002.
18. Pedersen SJ, Chiowchanwisawakit P, Lambert RG, et al. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation. J Rheumatol 2011;38:1349-54.
19. Chiowchanwisawakit P, Lambert RG, Conner-Spady B, et al. Focal fat lesions at vertebral corners on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis. Arthritis Rheum 2011;63:2215-25.
20. Maksymowych WP, Morency N, Conner-Spady B, et al. Suppression of inflammation and effects on new bone formation in ankylosing spondylitis: evidence for a window of opportunity in disease modification. Ann Rheum Dis 2013;72:23-8.
21. Dougados M, Braun J, Szanto S, et al. Continuous efficacy of etanercept in severe and advanced ankylosing spondylitis: results from a 12-week open-label extension of the SPINE study. Rheumatology (Oxford) 2012;51:1687-96.
22. Van Tubergen A, Van der Heijde D, Dougados M, et al. Are syndesmophytes most prevalent in the lumbar or in the cervical spine in patients with ankylosing spondylitis and do they develop in a specific direction? Rheumatology (Oxford) 2012;51:1432-9.
23. Machado P, Landewé R, Braun J, et al. Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitis. Ann Rheum Dis 2010;69:1465-70.
24. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and Safety of Infliximab In Patients With Ankylosing Spondylitis: Results of a Randomized, Placebo Controlled Trial (ASSERT). Arthritis and Rheumatism 2005;52:582-91.
25. Heldmann F, Brandt J, Van der Horst-Bruinsma IE, et al. The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 2011;29:672-80.
26. Wanders AJ, Landewe RB, Spoorenberg A, et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the Outcome Measures in Rheumatology Clinical Trials filter. Arthritis Rheum 2004;50:2622-32.
27. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009;60:717-27.
28. Dougados M, D'agostino MA, Benessiano J, et al. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. Joint Bone Spine 2011;78:598-603.
29. Sieper J, Appel H, Braun J, et al. Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes. Arthritis Rheum 2008;58:649-56.
30. Appel H, Kuhne M, Spiekermann S, et al. Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis. Arthritis Rheum 2006;54:2845-51.
31. Gong Y, Zheng N, Chen SB, et al. Ten years' experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheum 2012;64:1399-406.
32. Poddubnyy D, Conrad K, Syrbe U, et al. Elevated serum levels of the vascular endothelial growth factor is highly predictive for new syndesmophytes formation in patients with ankylosing spondylitis. Arthritis Rheum 2012;64(10 Suppl):S1054.
33. Liu Y, Berendsen AD, Jia S, et al. Intracellular VEGF regulates the balance between osteoblast and adipocyte differentiation. J Clin Invest 2012;122:3101-13.
34. Baraliakos X, Haibel H, Listing J, et al. Radiographic progression in ankylosing spondylitis-results after up to 8 years of anti-TNF treatment. Ann Rheum Dis 2011;70(Suppl3):344.
35. Sieper J, Van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815-22.
36. Baraliakos X, Listing J, Rudwaleit M, et al. Development of a radiographic scoring tool for ankylosing spondylitis only based on bone formation: addition of the thoracic spine improves sensitivity to change. Arthritis Rheum 2009;61:764-71.
37. Ramiro S, Van Tubergen A, Stolwijk C, et al. Scoring radiographic progression in ankylosing spondylitis: should we use the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) or the Radiographic Ankylosing Spondylitis Spinal Score (RASSS) ? Arthritis Res Ther 2013;15:R14.
38. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographic damage, elevated acute-phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheum 2012;64:1388-98.